CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...

Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...

Thank you for standing by. My name is Rochelle and I will be your conference operator today. At this time, I would like to welcome everyone to the Lineage Cell Therapeutics Fourth Quarter and Full ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

Russo Partners – Media Relations Nic Johnson or David Schull ([email protected]) ([email protected]) (212) 845-4242 Source: Lineage Cell Therapeutics, Inc. The views and ...

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...